Here’s Why Ziopharm Oncology Stock Was Obliterated Last Month

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 7 September, 2015 by The TZ Newswire Staff

Here’s Why Ziopharm Oncology Stock Was Obliterated Last Month

A shift in investor sentiment and a mixed second-quarter earnings report are all it took to send Ziopharm down by 35% in August. Does this stock stand a chance to recover?

See also
- Next Article China Financial Futures Exchange proposes circuit breakers for Chinese stock markets – Livesquawk
- Previous Article 3 Things Chipotle Mexican Grill Inc Is Doing Better Than Everyone Else
Editorial Calender

September 2015

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30

« Aug Oct »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 7 September, 2015 by The TZ Newswire Staff

Here’s Why Ziopharm Oncology Stock Was Obliterated Last Month

See also

Editorial Calender

Recent Tags